Reversibly Masked Polyamine for Targeted RNAi Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering RNAi triggers and other cell membrane-impermeable compounds into cells face significant barriers due to the complex cell membrane system, with existing transfection reagents causing toxicity and poor targeting in vivo, and existing RNAi delivery methods struggle with size limitations and adverse serum interactions.
Innovation Solution
Development of integrin-targeted, reversibly masked membrane active polyamines covalently linked to RNAi triggers, using RGD ligands and PEG dipeptide masking agents to facilitate targeted delivery to tumor cells while minimizing membrane disruptive activity and serum interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic transfection reagents are used to facilitate nucleic acid transfer and membrane disruption in vitro, then delivery efficiency is improved, but toxicity and adverse serum interactions increase in vivo
Solution Approach 1:
The patent applies dynamics by making the polyamine membrane activity reversible through pH-responsive conformational changes. The polyamine transitions from a membrane-disruptive state at endosomal pH to a membrane-inert state at physiological pH, allowing efficient delivery while minimizing in vivo toxicity. This dynamic behavior resolves the contradiction between delivery efficiency and safety.
Solution Approach 2:
The patent changes the pH parameter to control polyamine membrane activity. By designing the polyamine to be protonated at endosomal pH (enhancing membrane disruption) and deprotonated at physiological pH (reducing toxicity), the invention resolves the contradiction between effective delivery and minimal harm to healthy cells.
2Productivity
If membrane active polyamines are used to disrupt cell membranes for nucleic acid delivery, then delivery effectiveness is improved, but selective toxicity to healthy cells increases in vivo
Solution Approach 1:
The polyamine exhibits dynamic pH-responsive behavior, being membrane-active only in the acidic endosomal compartment and membrane-inert in the neutral pH environment of healthy cells. This spatially and temporally controlled activity resolves the contradiction between delivery effectiveness and selective toxicity.
Solution Approach 2:
The polyamine rushes through the endosomal membrane to release nucleic acids into the cytoplasm, then quickly becomes inert before causing harm to healthy cells. This rapid action and deactivation sequence minimizes exposure time to healthy tissue, resolving the toxicity contradiction.
3Stability of the object's composition
If large transfection reagent complexes are formed to protect nucleic acids, then stability is improved, but access to cells other than blood vessel cells is restricted in vivo
Solution Approach 1:
The polyamine acts as an intermediary that forms transient, moderate-size complexes with nucleic acids for protection during circulation, then disassembles at the target cell to enable entry. This intermediary behavior resolves the contradiction between stability during transport and accessibility during delivery.
Solution Approach 2:
The complex size and stability are dynamic rather than fixed. The polyamine-nucleic acid complexes adjust their size and stability in response to physiological conditions, being stable enough for circulation but small and flexible enough to access various cell types in vivo.
4Stability of the object's composition
If high negative charge is introduced to RNAi triggers for stability, then nucleic acid stability is improved, but targeted delivery is inhibited by interference with receptor binding
Solution Approach 1:
The invention creates a composite system where the polyamine (positive charge) and RNAi trigger (negative charge) form a neutral or near-neutral complex. This composite approach allows the RNAi trigger to maintain its negative charge for stability while the polyamine countercharge enables targeted delivery by reducing electrostatic interference with receptor binding.
Solution Approach 2:
The polyamine and RNAi trigger are merged into a single conjugate molecule, combining the stability-providing negative charge of the RNAi trigger with the delivery-enabling positive charge of the polyamine. This merging resolves the contradiction by integrating both functional requirements into one molecule.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enables efficient, targeted delivery of RNAi triggers to tumor cells, inhibiting gene expression through interaction with endogenous RNA interference pathways, while maintaining stability and bioavailability, thus offering a therapeutic option for cancer treatment.
Implementation Method 1
RGD ligands and PEG dipeptide masking agents to facilitate targeted delivery to tumor cells
Implementation Method 2
membrane disruptive activity of a membrane active polyamine using reversible physiologically labile masking
Implementation Method 3
inhibiting gene expression through interaction with endogenous RNA interference pathways
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 2D~2F
AI summary
The present invention is directed compositions for delivery of RNA interference (RNAi) triggers to integrin positive tumor cells in vivo. The compositions comprise RGD ligand- targeted amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or conjugate) are further covalently linked to an RNAi trigger.